

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/593,941
Applicant : Civelli, et al.
Filed : 09/22/2006
TC/A.U. : 1626
Examiner : Not Assigned
Confirmation No. : 5412
Docket No. : UCIVN-068US
Customer No. : 33197
Title : Melanin-Concentrating Hormone Receptor Antagonists and Methods of Use

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the office action dated July 13, 2011, Applicant provisionally elects to prosecute composition claims 1-24 (Group I). No proposed species are identified in the office action. Claims 1-24 share a common general formula and are believed to form a single patentably distinct species. Accordingly, the species of claims 1-24 is also provisionally elected.

The filing fees due for this response are being paid electronically concurrently with filing. The Commissioner is hereby authorized to change any underpayment, or to credit any over payment, to Deposit Account No.50-0878.

Respectfully submitted,
Stout, Uxa, Buyan & Mullins, LLP

Date: November 14, 2011

/Robert D. Buyan/

Robert D. Buyan, Reg. No. 32,460

4 Venture, Suite 300
Irvine, CA 92618
Telephone: (949) 450-1750, Facsimile: (949) 450-1764